Biotech Losers: MannKind Corporation (NASDAQ:MNKD), Rexahn Pharmaceuticals (NYSEMKT:RNN), ZIOPHARM Oncology (NASDAQ:ZIOP), Seattle Genetics (NASDAQ:SGEN)

Gilead Sciences GILD NASDAQ:GILD

MannKind Corporation (NASDAQ:MNKD) announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA(R) by three months to July 15, 2014 in order to provide time for a full review of information submitted by MannKind in response to the FDA’s requests.MannKind Corporation (NASDAQ:MNKD) stock performance was -6.42% in last session and finished the day at $6.41. Traded volume was 13.70million shares in the last session and the average volume of the stock remained 10.43million shares. The beta of the stock remained 1.48. MannKind Corporation (NASDAQ:MNKD) insider ownership is 0.60%.

Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and financial results for the year ended December 31, 2013. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) dropped -6.03 percent to $1.09 Friday on volume of 4.53million shares. The intra-day range of the stock was $1.09 to $1.14. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) has a market capitalization of $192.42million.

Amgen and ZIOPHARM carry a Zacks Rank #1 (Strong Buy). ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s stock on Apr 11, 2014 reported a decrease of -6.74% to the closing price of $3.60. Its fifty two weeks range is $1.55-$5.58. The total market capitalization recorded $362.00million. The overall volume in the last trading session was 2.60million shares. In its share capital, ZIOP has 100.56million outstanding shares.

Seattle Genetics, Inc. (NASDAQ:SGEN) has earned a milestone payment of $6 million from Takeda Pharmaceutical Company Limited ( TKPYY ) following the first commercial sales of Adcetris in key countries (Australia, South Korea and Mexico). On Friday, shares of Seattle Genetics, Inc. (NASDAQ:SGEN) dropped -5.59% to close the day at $37.17. Company return on investment (ROI) is 27.30% and its monthly performance is recorded as -25.69%. Seattle Genetics, Inc. (NASDAQ:SGEN) quarterly revenue growth is -13.50%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone